REG - Faron Pharma. Oy - Grant of options

Faron Pharmaceuticals OyAnnouncement

04/12/2023 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20231204:nRSD4715Va&default-theme=true

RNS Number : 4715V  Faron Pharmaceuticals Oy  04 December 2023

Faron Pharmaceuticals Ltd

("Faron" or the "Company")

Grant of options

Company announcement, December 4, 2023 at 9 am (EET) / 7 am (GMT)

TURKU, FINLAND / BOSTON, MA - Faron Pharmaceuticals Ltd (AIM: FARN, First
North: FARON), a clinical stage biopharmaceutical company focused on building
the future of immunotherapy by harnessing the power of the immune system to
tackle cancer and inflammation, today announces that the Company's board has
confirmed the grant of a total of 34,000 options over ordinary shares in the
Company ("Options") under the Company's Share Option Plan 2019 (including its
UK and US sub plans). The Options have been allocated under the Share Option
Plan 2019 and are exercisable between9 November 2024 and 9 November 2028,
vesting 25% per annum over four years. The exercise price for Options
allocated under the Share Option plan is €3,53 per share, which is
calculated based on the average price per share at which the ordinary shares
in the Company have been traded on AIM for 90 days preceding the allocation
date of 9 November 2023. The exercise price for Options allocated under the US
sub plan is €3,35 per share, which is calculated based on the average price
per share at which the ordinary shares in the Company have been traded on AIM
for 30 days preceding the allocation date of 9 November 2023. The terms of the
Share Option Plan 2019 are available on the Company's website at
https://www.faron.com/investors/general-meetings/2020.

The granted 34,000 Options entitle the option holders to subscribe for a total
of 34,000 new ordinary shares in the Company, if exercised in full, and
represent 0,05% of the fully diluted ordinary share capital of the Company.

Included in the number of Options granted are the following Options which were
issued to directors, other persons discharging managerial responsibilities
("PDMRs"), scientific advisory board ("SAB") members and Company personnel:

Director
 
Options granted

Christine
Roth
                                30,000

Total directors
 
                                30,000

 

Total Company
personnel
  4,000

 

 

For more information please contact:

 

Investor Contact

LifeSci Advisors 

Daniel Ferry 

Managing Director 

daniel@lifesciadvisors.com 

+1 (617) 430-7576 

 

Cairn Financial Advisers LLP, Nomad

Sandy Jamieson, Jo Turner

Phone: +44 (0) 207 213 0880

 

Peel Hunt LLP, Broker

Christopher Golden, James Steel

Phone: +44 (0) 20 7418 8900

 

Sisu Partners Oy, Certified Adviser on Nasdaq First North

Juha Karttunen

Phone: +358 (0)40 555 4727

Jukka Järvelä

Phone: +358 (0)50 553 8990

 

About Faron Pharmaceuticals Ltd. 

Faron (AIM: FARN, First North: FARON) is a global, clinical-stage
biopharmaceutical company, focused on tackling cancers via novel
immunotherapies. Its mission is to bring the promise of immunotherapy to a
broader population by uncovering novel ways to control and harness the power
of the immune system. The Company's lead asset is bexmarilimab, a novel
anti-Clever-1 humanized antibody, with the potential to remove
immunosuppression of cancers through targeting myeloid cell
function. Bexmarilimab is being investigated in Phase I/II clinical trials
as a potential therapy for patients with hematological cancers in combination
with other standard treatments. Further information is available
at www.faron.com
(https://eur01.safelinks.protection.outlook.com/?url=http%3A%2F%2Fwww.faron.com%2F&data=05%7C01%7C%7Ca4ae0afa96854c5c5f2a08db771ae20d%7Ca2d9b7a432f64a96b03727499230d5fd%7C1%7C0%7C638234729855975666%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%3D%7C3000%7C%7C%7C&sdata=%2FNadoN9wXIGZtfCkFVuLSTXPpNg3%2BBXoRfIQaIPce6k%3D&reserved=0)
.

 

 Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No.
 596/2014
 1   Details of the person discharging managerial responsibilities/person closely
     associated
 a.  Name                                                         Christine Roth
 2   Reason for notification

 a.  Position/Status                                              Person discharging managerial responsibilities/person closely associated
 b.  Initial notification/                                        Initial notification

     Amendment
 3   Details of the issuer, emission allowance market participant, auction
     platform, auctioneer or auction monitor
 a.  Name                                                         Faron Pharmaceuticals Oy
 b.  LEI                                                          7437009H31TO1DC0EB42
 4   Details of the transaction(s): section to be repeated for (i) each type of
     instrument; (ii) each type of transaction; (iii) each date; and (iv) each
     place where transactions have been conducted
 a.  Description of the financial instrument, type of instrument  Options over ordinary shares

Identification Code
ISIN: FI4000153309
 b.  Nature of the transaction                                    Grant of options made under the Faron Share Option Plan 2019 US sub plans
                                                                  exercisable at €3.35 per ordinary share.
 c.  Price(s) and volume(s)
                                                                               Price(s)     Volume(s)
     Nil                                                                       30,000

 d.  Aggregated information

     - Aggregated Volume

                                                                  30,000

     - Price

                                                                  Nil

 e.  Date of the transaction                                      1 December 2023
 f.  Place of the transaction                                     Turku

 

 

d.

Aggregated information

 

- Aggregated Volume

 

- Price

 

 

 

30,000

 

Nil

 

 

e.

Date of the transaction

1 December 2023

f.

Place of the transaction

Turku

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  DSHNKDBPOBDDCBK